Drugs / piperacillin/tazobactam
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07484633 | Apr 2026 → Apr 2028 expected | infectious disease with sepsis | Semmelweis University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | piperacillin/tazobactam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07484633 ↗ |
| Known as | TZP | “piperacillin/tazobactam (TZP): 90 mg/kg piperacillin q6h for non-immunosuppressed patients and 100 mg/kg piperacillin q6h for immunosuppressed patients (max. 4.5 g...” NCT07484633 ↗ |